RxDoctor Payments Data

Krishnan Challappa, MD

Cardiology · Elizabethtown, KYNPI 1942202676

Payments from drug & device makers

$33,129in general payments, 2019–2025

Across 341 payments — averaging $97.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim Pharma GmbH & Co.kg$12K
  • Novo Nordisk AS$9K
  • AstraZeneca$5K
  • Boehringer Ingelheim International GmbH$4K
  • Novartis$517
  • Merck$515
  • plus $2K from 18 others
$6,840in research payments, 2019–2025

Across 1 payment — averaging $6840.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boehringer Ingelheim$7K

What the payments were for

  • Speaking & faculty fees$4,90066%
  • Travel & lodging$581%
  • Food & beverage$2,35832%
  • Education$811%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few cardiology providers in Kentuckyto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$259,682
Medicare patients
1,684
Services billed
3,737

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban526$568,851
XareltoRivaroxaban55$59,041
EntrestoSacubitril/Valsartan46$39,914
BrilintaTicagrelor48$29,469
Repatha SureclickEvolocumab37$21,950
FarxigaDapagliflozin Propanediol34$21,720
Metoprolol Succinate909$11,851
VascepaIcosapent Ethyl16$5,124
Carvedilol645$3,597
Prasugrel Hcl19$3,465
Atorvastatin Calcium423$3,009
Diltiazem 24hr Er (Cd)Diltiazem Hcl115$2,933
ClopidogrelClopidogrel Bisulfate324$2,751
Losartan Potassium388$2,662
Amiodarone Hcl81$2,082

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$290$568,851526 claims
Johnson & JohnsonXarelto$422$59,04155 claims
AstraZenecaBrilinta, Farxiga$5,231$51,18982 claims
NovartisEntresto$517$39,91446 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cardiology providers in Kentuckyon file to place this against a meaningful peer group, so we don't.

Other cardiology in Elizabethtown

Where these figures come from

Is this you, or does something look wrong? →